Correlation of Adiponectin With Testosterone in Patients With and Without Type 2 Diabetes and Erectile Dysfunction

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Urology

Background:

• Erectile dysfunction (ED) is a common complication of type 2 diabetes mellitus (T2DM).
• Adiponectin, an adipokine, plays a role in metabolic regulation and cardiovascular health.
• The relationship between adiponectin, testosterone, and ED in diabetic patients requires further investigation.

Purpose of the Study:

• To compare adiponectin levels in diabetic patients with and without ED.
• To investigate the correlation between adiponectin, testosterone, and ED severity (IIEF scores) in diabetic and non-diabetic individuals.

Main Methods:

• Cross-sectional study involving three groups: T2DM with ED, T2DM without ED, and non-diabetic with ED (n=29 each).
• Assessed fasting blood glucose, insulin, HOMA-IR, testosterone, and adiponectin levels.
• Administered the International Index of Erectile Function (IIEF) questionnaire.

Main Results:

• Adiponectin levels were significantly lower in diabetic patients with ED compared to non-diabetic patients with ED and diabetic patients without ED (p < .01).
• Testosterone levels were lower in diabetic patients with ED than in diabetic patients without ED (p = .024).
• Testosterone showed a positive correlation with adiponectin (r = .371, p = .001), but neither correlated with IIEF scores.

Conclusions:

• Reduced adiponectin and testosterone are associated with ED in T2DM.
• Circulating adiponectin and testosterone levels are positively correlated in patients with ED.
• Adiponectin and testosterone levels do not correlate with the severity of ED as measured by IIEF.